Preliminary results from phase I/II lung cancer trial of mimotuzumab are positive

Published: 2007-09-13 06:56:00

Updated: 2007-09-13 06:56:00

YM BioSciences Inc., a Canada-based oncology company, announced on September 4 the positive preliminary results from the first two cohorts of the Phase I part of a Phase I/II trial of nimotuzumab in combination with radiation for the treatment of non-small-cell lung cancer (NSCLC) patients who are unsuitable for radical chemotherapy.

The data were reported on September 5 in a poster presenta...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.